Slow Alzheimer’s diagnoses ‘mean UK patients missing out on experimental treatments’
Summary
People with Alzheimer's disease in the UK often get diagnosed too late or not clearly enough. This delay means many cannot join clinical trials for new treatments, which limits their access to experimental medicines.Key Facts
- A UK charity says slow or unclear Alzheimer’s diagnoses keep patients from joining drug trials.
- Clinical trials for Alzheimer’s drugs have reached a record number globally this year.
- Over 32 million people worldwide have Alzheimer’s, but diagnosis can take years.
- About one in three people with Alzheimer’s in the UK is not formally diagnosed.
- New drugs like lecanemab and donanemab have been approved and can slow disease progression slightly.
- Some experts say these drugs may work better if used earlier and for longer times.
- Alzheimer’s drug trials are shifting from only targeting amyloid protein to also focusing on tau protein and inflammation.
- Fewer than 1,000 patients in the UK are involved in late-stage Alzheimer’s drug trials because of diagnosis problems.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.